A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.
Condition or disease
Cytomegalovirus RetinitisHIV Infections
Patients receive valganciclovir twice a day for 21 days as induction therapy then daily as maintenance therapy. Patients are encouraged to remain on study for at least 3 months and will remain until common study closure.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Allowed with caution:
Patients must have:
HIV infection with CMV retinitis.
Minimum of 4 weeks prior treatment with ganciclovir, foscarnet, or cidofovir.
Intraocular implant in either or both eyes, as long as CMV retinitis is active in one eye, upon approval by Roche.
Patients with any of the following symptoms of conditions are excluded:
Active extraocular CMV disease.
Severe uncontrolled diarrhea or evidence of malabsorption.
CMV hyperimmune globulin.
Patients with the following prior conditions are excluded:
Ocular media opacities (corneal, aqueous, lens, or vitreous) preventing ophthalmologic retinal assessment.
Simultaneous participation in another study (unless approved by Roche).
A minimum of 4 weeks treatment with ganciclovir, foscarnet, or cidofovir.
Approval required for prior use of investigational anti-CMV agents.